Annovis Bio, Inc.
Symbol: ANVS (NYSE)
2.54
▼ (-6.92%) -0.189
Company Description:
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Key Stats
- Today's Open: $2.575
- Today's High: $2.585
- Today's Low: $2.49
- Today's Volume: 85.57K
- Yesterday Close: $2.73
- Yesterday High: $2.77
- Yesterday Low: $2.65
- Yesterday Volume: 143.36K
- Last Min Volume: 0
- Last Min High: $2.565
- Last Min Low: $2.541
- Last Min VWAP: $0
Company Profile
- Name: Annovis Bio, Inc.
- Website: https://www.annovisbio.com
- Listed Date: 2020-01-29
- Location: MALVERN, PA
- Market Status: Active
- CIK Number: 0001477845
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $48.91M
- Round Lot: 100
- Outstanding Shares: 19.49M
- Asset Type: CS
RECENT FILINGS FOR ANVS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-06-23 | 8-K | View |
| 2025-06-20 | 8-K | View |
| 2025-06-18 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-11 | 4 | View |
| 2025-06-05 | 4 | View |
| 2025-06-02 | 4 | View |
| 2025-05-16 | 3 | View |
| 2025-05-13 | 8-K | View |
| 2025-05-13 | 10-Q | View |
| 2025-05-12 | SCHEDULE 13G/A | View |
| 2025-05-01 | ARS | View |
| 2025-05-01 | DEFA14A | View |
| 2025-04-30 | DEF 14A | View |
| 2025-03-27 | 8-K | View |
| 2025-03-21 | 10-K | View |
| 2025-03-21 | 8-K | View |
| 2025-02-10 | SCHEDULE 13G | View |
| 2025-02-05 | 8-K | View |
| 2025-02-05 | 8-K | View |
Latest News on ANVS